AstraZeneca PLC (AZN)vsVericel Corp Ord (VCEL)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
VCEL
Vericel Corp Ord
$34.73
+3.89%
HEALTHCARE · Cap: $1.82B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 21162% more annual revenue ($58.74B vs $276.26M). AZN leads profitability with a 17.4% profit margin vs 6.0%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
VCEL
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-48.8%
Fair Value
$23.27
Current Price
$34.73
$11.46 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 24.1%
Revenue surging 23.3% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 5.1% — below average capital efficiency
6.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : VCEL
The strongest argument for VCEL centers on Operating Margin, Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : VCEL
The primary concerns for VCEL are Market Cap, Return on Equity, Profit Margin. A P/E of 111.4x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while VCEL is a growth play — different risk/reward profiles.
VCEL carries more volatility with a beta of 1.21 — expect wider price swings.
VCEL is growing revenue faster at 23.3% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 48/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Vericel Corp Ord
HEALTHCARE · BIOTECHNOLOGY · USA
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?